Pharmcoeconomics of Budesonide/Formoterol versus Fluticasone/Salmeterol for Asthma:a Systematic Review
10.6039/j.issn.1001-0408.2015.18.27
- VernacularTitle:布地奈德/福莫特罗对比氟替卡松/沙美特罗治疗哮喘的药物经济学的系统评价
- Author:
Haiyin WANG
;
Jiangjiang HE
;
Xia LING
- Publication Type:Journal Article
- Keywords:
Budesonide/formoterol;
Fluticasone/salmeterol;
Asthma;
Pharmacoeconomics;
Systematic review
- From:
China Pharmacy
2015;(18):2527-2529
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To review economics of budesonide/formoterol and fluticasone/salmeterol for asthma systematically, and to provide evidence-based basis for rational selection of drug to treat asthma. METHODS:Retrieved from Medline,EMBase, EBM reviews (HTA,NHSEED),CBM,CJFD,Wanfang database,researches about pharmacoeconomics of budesonide/formoterol (test group) versus fluticasone/salmeterol (control group)for asthma were collected,and analyzed with qualitative systematic re-view method. RESULTS:A total of 7 researches and 13 comparative data were included,containing 6 682 patients. The incidence of severe acute asthma of test group were lower than those of control group,with significant difference(P<0.05). The total costs and direct costs of test group were lower than those of control group. Good effect had been achieved in test group with low cost. CONCLUSIONS:Budesonide/formoterol is more cost-effective than fluticasone/salmeterol in teenagers patients and adults who fail to control asthma. Due to limitation of included studies,large-scale and high-quality studies are required for further validation of the conclusion.
